Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Francois Brisebois
LIFE
Francois Brisebois
Wall Street Analyst
★★☆☆☆
#2099
on 13Foresight · ranked by our own returns
53%
Success Rate
+9.3%
Average Return
17 of 32 calls profitable · -4.2% vs benchmark
📈 Across the calls we could measure, roughly 53% of Francois Brisebois's ratings turned a profit when each position was held for 1 year — averaging +9.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

120 Buy 4 Hold 0 Sell
Francois's Stock Coverage 40 ratings · 2026-06-18
Company Date Position Consensus Price Target 1-Yr Return
IRD
Opus Genetics
Jun 17, 2026 BUY Strong Buy
+155.2% avg upside
23 analysts
$10.00
146.38% Upside
·
SVRA
Savara
Jun 09, 2026 BUY Strong Buy
+60.7% avg upside
17 analysts
$10.00
85.97% Upside
·
DFTX
Definium Therapeutics
Jun 06, 2026 BUY Strong Buy
+46.3% avg upside
20 analysts
$44.00
80.02% Upside
+6.1%
DYN
Dyne Therapeutics
Jun 03, 2026 BUY Strong Buy
+98.3% avg upside
29 analysts
$44.00
129.25% Upside
+4.1%
CMPS
COMPASS Pathways
Jun 02, 2026 BUY Strong Buy
+68.1% avg upside
18 analysts
$23.00
92.62% Upside
-10.4%
PRAX
Praxis Precision Medicines
Jun 02, 2026 BUY Strong Buy
+96.4% avg upside
24 analysts
$731.00
170.67% Upside
+3.2%
OVID
Ovid Therapeutics
May 16, 2026 BUY Strong Buy
+98.5% avg upside
17 analysts
$5.00
106.56% Upside
·
LRMR
Larimar Therapeutics
May 16, 2026 BUY Strong Buy
+421.7% avg upside
21 analysts
$25.00
606.26% Upside
+4.9%
MPLT
MapLight Therapeutics, Inc.
May 15, 2026 BUY Strong Buy
+30.8% avg upside
11 analysts
$45.00
54.02% Upside
-5.5%
AQST
Aquestive Therapeutics
May 15, 2026 BUY Strong Buy
+100.1% avg upside
10 analysts
$9.00
103.07% Upside
+3.2%
TARS
Tarsus Pharmaceuticals
May 09, 2026 BUY Strong Buy
+21.3% avg upside
16 analysts
$95.00
51.86% Upside
+6.9%
CNTA
Centessa Pharmaceuticals
Apr 01, 2026 HOLD Buy
-14.1% avg upside
19 analysts
-0.0%
KALA
KALA BIO
Oct 24, 2025 HOLD Strong Buy
+7343.1% avg upside
9 analysts
-93.4%
HRMY
Harmony Biosciences Holdings
Apr 08, 2025 BUY Strong Buy
+38.7% avg upside
13 analysts
$61.00
80.73% Upside
+1.2%
SLP
Simulations Plus
Apr 04, 2025 BUY Buy
+89.9% avg upside
11 analysts
$65.00
256.22% Upside
-53.3%
FTH
Faeth Therapeutics
Mar 28, 2025 BUY Strong Buy
+121.6% avg upside
11 analysts
$80.00
380.55% Upside
·
ABEO
Abeona Therapeutics
Mar 20, 2025 BUY Strong Buy
+200.8% avg upside
17 analysts
$16.00
183.25% Upside
-13.4%
ALDX
Aldeyra Therapeutics
Mar 03, 2025 BUY Strong Buy
+753.6% avg upside
21 analysts
$12.00
555.75% Upside
-15.7%
TRDA
Entrada Therapeutics Inc
Feb 28, 2025 BUY Strong Buy
+210.2% avg upside
10 analysts
$30.00
340.56% Upside
-0.1%
ACHV
Achieve Life Sciences
Jan 08, 2025 BUY Strong Buy
+194.1% avg upside
12 analysts
$11.00
105.26% Upside
+55.4%
BCRX
BioCryst
Aug 26, 2024 HOLD Strong Buy
+102.2% avg upside
24 analysts
+4.2%
HELP
Helus Pharma
Aug 26, 2024 HOLD Strong Buy
+884.5% avg upside
12 analysts
·
MDWD
Mediwound
Jul 29, 2024 BUY Strong Buy
+52.4% avg upside
13 analysts
$36.00
153.60% Upside
+2.4%
DMAC
Diamedica Therapeutics
Jul 01, 2024 BUY Strong Buy
+158.2% avg upside
12 analysts
$6.00
4.69% Upside
+21.0%
BNGO
BioNano Genomics
Aug 17, 2023 BUY Strong Buy
+713.5% avg upside
9 analysts
$20.00
1624.23% Upside
-82.2%
PCSA
Processa Pharmaceuticals
Apr 03, 2023 BUY Strong Buy
+1986.4% avg upside
5 analysts
$60.00
2690.68% Upside
-75.7%
SERA
Sera Prognostics
Mar 23, 2023 BUY Strong Buy
+300.0% avg upside
7 analysts
$5.00
164.46% Upside
+163.8%
NMTRQ
9 Meters Biopharma
Sep 27, 2022 BUY Buy
+3234374900.0% avg upside
11 analysts
$100.00
9999999900.08% Upside
·
MDXH
MDxHealth
Jul 18, 2022 BUY Strong Buy
+1037.7% avg upside
8 analysts
$18.00
3104.56% Upside
-48.5%
CELC
Celcuity
May 11, 2020 BUY Strong Buy
+41.4% avg upside
16 analysts
·
GLMD
Galmed Pharmaceuticals
Feb 04, 2020 BUY Buy
+3982.5% avg upside
13 analysts
$18.00
2898.94% Upside
-18.7%
TLSA
Tiziana Life Sciences
Sep 10, 2019 BUY Strong Buy
+525.8% avg upside
5 analysts
$4.00
270.39% Upside
+136.0%
EBS
Emergent Biosolutions
Sep 04, 2019 BUY Buy
+211.6% avg upside
9 analysts
$72.00
784.57% Upside
+87.1%
ARDS
Aridis Pharmaceuticals
Sep 04, 2019 BUY Strong Buy
+427319.4% avg upside
5 analysts
$15.00
483770.93% Upside
-40.8%
CLSDQ
Clearside Biomedical
Aug 22, 2019 HOLD Hold
+139900.0% avg upside
10 analysts
$1.00
4900.10% Upside
+134.9%
SDEV
Stablecoin Development Corp
Jul 29, 2019 HOLD Buy
+8.1% avg upside
7 analysts
$1.00
15.95% Downside
·
MTVA
MetaVia
Jun 27, 2019 BUY Strong Buy
+1656.7% avg upside
13 analysts
$50.00
2823.97% Upside
-54.6%
STEX
Streamex
Feb 20, 2019 BUY Strong Buy
+905.0% avg upside
5 analysts
$10.50
1025.72% Upside
·
TVRD
Tvardi Therapeutics
May 24, 2018 BUY Buy
+601.3% avg upside
23 analysts
$26.00
907.69% Upside
+16.0%
HEPA
Hepion Pharmaceuticals
Feb 13, 2018 BUY Strong Buy
+62892.6% avg upside
9 analysts
$210.00
262399.94% Upside
·
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Francois Brisebois — Frequently Asked Questions
How accurate are Francois Brisebois's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Francois's ratings were profitable over a one-year hold, with an average return of +9.3% per rating, or -4.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Francois ranked on 13Foresight?
Francois Brisebois is currently ranked #2099 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Francois cover?
Francois most recently has ratings on IRD, SVRA, DFTX, DYN, CMPS, PRAX, OVID, LRMR, MPLT, AQST, TARS, CNTA and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.